Uğur Şahin and Özlem Türeci, the two German researchers of Turkish origin who founded the German company BioNTech – which created the first effective vaccine against the coronavirus pandemic developed in Europe – have announced that the cancer vaccine they are developing has succeeded in early tests not only in slowing the growth of tumours, but also in reducing their size.
The announcement was made at the European Society for Medical Oncology (ESMO) congress held in Madrid, where Şahin and Türeci explained that the vaccine, based on messenger RNA (mRNA) technology already used against the SARS-CoV-2 virus that triggered the pandemic, was administered in four doses to a group of 44 patients, 59% of whom experienced a reduction in tumour size of at least 30%; In addition, in 95% of the test participants, the tumour stabilised and stopped growing after the vaccine, which in about half of the patients caused mild side effects, including swelling, low blood pressure, or increased body temperature. BioNTech aims to treat 10,000 patients with its new cancer vaccine by 2030.
VOTE
EDITORIAL TEAM
🧿 About us
.
Edited and reviewed by:
Pablo Gómez is a specialist in Turkey and has been editor-in-chief of Hispanatolia since 2011. He has been analysing current affairs and geopolitics in Turkey and the surrounding region since 2006.
…
📣 Your ADVERTISING on Hispanatolia
.
🤗 HELP US WITH A DONATION:
💗 Paypal
